Sienna Biopharmaceuticals (NASDAQ:SNNA) posted its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.03), MarketWatch Earnings reports.
Shares of NASDAQ SNNA traded down $0.52 during midday trading on Friday, hitting $10.05. The company’s stock had a trading volume of 26,504 shares, compared to its average volume of 82,323. Sienna Biopharmaceuticals has a one year low of $8.77 and a one year high of $25.71. The company has a quick ratio of 5.82, a current ratio of 5.82 and a debt-to-equity ratio of 0.54. The firm has a market cap of $211.53 million, a P/E ratio of -1.94 and a beta of 1.48.
Several research firms have recently issued reports on SNNA. Zacks Investment Research lowered shares of Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 3rd. BMO Capital Markets lowered their price target on shares of Sienna Biopharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 1st.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Further Reading: Technical Analysis
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.